Show simple item record

dc.contributor.authorPavlovic, Kristina
dc.contributor.authorTristán Manzano, María 
dc.contributor.authorMaldonado Pérez, Noelia 
dc.contributor.authorCortijo Gutierrez, Marina
dc.contributor.authorSánchez Hernández, Sabina
dc.contributor.authorJusticia Lirio, Pedro
dc.contributor.authorMartín Molina, Francisco 
dc.contributor.authorBenabdellah, Karim
dc.identifier.citationPavlovic K, Tristán-Manzano M, Maldonado-Pérez N, Cortijo-Gutierrez M, Sánchez-Hernández S, Justicia-Lirio P, Carmona MD, Herrera C, Martin F and Benabdellah K (2020) Using Gene Editing Approaches to Fine-Tune the Immune System. Front. Immunol. 11:570672. [doi: 10.3389/fimmu.2020.570672]es_ES
dc.description.abstractGenome editing technologies not only provide unprecedented opportunities to study basic cellular system functionality but also improve the outcomes of several clinical applications. In this review, we analyze various gene editing techniques used to finetune immune systems from a basic research and clinical perspective. We discuss recent advances in the development of programmable nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)-Cas-associated nucleases. We also discuss the use of programmable nucleases and their derivative reagents such as base editing tools to engineer immune cells via gene disruption, insertion, and rewriting of T cells and other immune components, such natural killers (NKs) and hematopoietic stem and progenitor cells (HSPCs). In addition, with regard to chimeric antigen receptors (CARs), we describe how different gene editing tools enable healthy donor cells to be used in CAR T therapy instead of autologous cells without risking graft-versus-host disease or rejection, leading to reduced adoptive cell therapy costs and instant treatment availability for patients. We pay particular attention to the delivery of therapeutic transgenes, such as CARs, to endogenous loci which prevents collateral damage and increases therapeutic effectiveness. Finally, we review creative innovations, including immune system repurposing, that facilitate safe and efficient genome surgery within the framework of clinical cancer immunotherapies.es_ES
dc.description.sponsorshipSpanish ISCIII Health Research Fundes_ES
dc.description.sponsorshipEuropean Union (EU) PI12/01097 PI15/02015 PI18/00337 PI18/00330es_ES
dc.description.sponsorshipCECEyU and CSyF councils of the Junta de Andalucia FEDER/European Cohesion Fund (FSE) 2016000073391-TRA 2016000073332-TRA PI-57069 PAIDI-Bio326 PI-0014-2016es_ES
dc.description.sponsorshipNicolas Monardes regional Ministry of Health 0006/2018es_ES
dc.description.sponsorshipSpanish Government FPU16/05467 FPU17/02268es_ES
dc.description.sponsorshipIndustrial Doctorate Plan MCI DIN2018-010180es_ES
dc.description.sponsorshipSMSI PEJ-2018-001760-Aes_ES
dc.description.sponsorshipLentiStem Bioteches_ES
dc.publisherFrontiers Media SAes_ES
dc.rightsAtribución 3.0 España*
dc.subjectImmunotherapy es_ES
dc.subjectGene editinges_ES
dc.subjectGraft-vs-host diseasees_ES
dc.subjectBase editorses_ES
dc.titleUsing Gene Editing Approaches to Fine-Tune the Immune Systemes_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España